Search clinical trials for: MEDI8897 25 mg

Total 10588 results

MedImmune LLC

Completed

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants (MEDI8897 1b)

Respiratory Syncytial Virus

United States, South Africa, Chile
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
AstraZeneca
IQVIA RDS (Shanghai) Co., Ltd.

Completed

Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults (PK/ADA)

Evaluate PK Profile

China
Zydus Lifesciences Limited

Recruiting

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

India
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
AstraZeneca

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) (MELODY)

Respiratory Syncytial Virus Infections

United States, Finland, Spain, Belgium, France, Korea, Republic of, Turkey, Austria, New Zealand, South Africa, Australia, Germany, Bulgaria, United Kingdom, Ukraine, Argentina, Czechia, Panama, Estonia, Lithuania, Poland, Japan, Co... and more
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab (JUBILUS)

Respiratory Syncytial Virus Infections

Japan
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Healthy

United States
Repros Therapeutics Inc.

Completed

Proellex® Pharmacokinetic Bridging Study II (PK)

Healthy

United States
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
MedImmune LLC

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. (MEDI8897 Ph2b)

Respiratory Syncytial Virus Infections

United States, Canada, Finland, France, Italy, Spain, Belgium, Hungary, Turkey, United Kingdom, New Zealand, Brazil, South Africa, Australia, Bulgaria, Czechia, Poland, Estonia, Lithuania, Chile, Latvia, Sweden, Argentina
Insmed Incorporated

Completed

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis

United States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany, Australia, Canada, Denmark, Italy, Poland, Serbia, Spain, Switzerland
Novartis Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Cytopaenia

Japan
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Multiple Sclerosis Extension Study, Phase II (ATAMS ext)

Relapsing Multiple Sclerosis

Sweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
NYU Langone Health

Completed

A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

COVID-19

United States
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (EARLY)

Asymptomatic Amyloid-positive

United States, Canada, United Kingdom, Belgium, Germany, Spain, Japan, Australia, Netherlands, Denmark, Mexico, Finland, Sweden
Novartis Pharmaceuticals

Completed

Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

Aplastic Anemia

China
Xinnate AB
Region Skane

Completed

Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.

Blister | Epidermolysis Bullosa | Wound of Skin | Varicose Ulcer of Lower Limb

Sweden
Idorsia Pharmaceuticals Ltd.

Recruiting

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

Insomnia

Spain, United States, Belgium, Germany, Bulgaria
Haisco Pharmaceutical Group Co., Ltd.

Completed

Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

Type 2 Diabetes Mellitus

China
GlaxoSmithKline

Completed

The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis

Gastroparesis

Belgium, Sweden
Insmed Incorporated

Active, not recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Non-Cystic Fibrosis Bronchiectasis

New Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
Repros Therapeutics Inc.

Terminated

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Uterine Fibroids

United States
Eisai Inc.

Completed

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Healthy Volunteers

United States
Future University in Egypt

Completed

Partially Replicate Bioequivalence Study of Quetiapine 25 mg in Healthy Volunteers Under Fasting Condition

Bioequivalence

Egypt
AstraZeneca
IQVIA RDS Inc.

Recruiting

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China (CHIMES)

Lower Respiratory Tract Infection

China
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Pfizer

Completed

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Migraine

Japan
Idorsia Pharmaceuticals Ltd.

Completed

A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Insomnia Disorder

United States, Germany, Canada, Denmark, Poland, Spain, Switzerland, Belgium, Bulgaria, Finland, France, Hungary, Korea, Republic of, Sweden
GSNOR Therapeutics, Inc.

Unknown

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)
Eupraxia Pharmaceuticals Inc.
NBCD A/S

Completed

Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee

Osteoarthritis, Knee

Poland, Czechia, Denmark
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

PRC-063 in Adolescent ADHD

ADHD

United States, Canada
Rhodes Pharmaceuticals, L.P.
Purdue Pharma, Canada

Completed

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

ADHD

United States, Canada
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Diabetes Mellitus, Type 2

China
AstraZeneca
Iqvia Pty Ltd

Completed

Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children (MUSIC)

RSV Infection

United States, Belgium, Spain, Japan, Poland, South Africa, United Kingdom, Ukraine
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)

Resistant Hypertension

Spain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
Takeda

Completed

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease

Type 2 Diabetes Mellitus

Japan
Cinclus Pharma Holding AB

Active, not recruiting

Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects

GERD

Slovenia
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Withdrawn

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease. (INSPIRE-CKD)

Hypertension | Renal Insufficiency, Chronic
Repros Therapeutics Inc.

Completed

Proellex Pharmacokinetics Bridging Study

Healthy

United States
Repros Therapeutics Inc.

Terminated

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Uterine Fibroids

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
GlaxoSmithKline

Completed

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

Gastroparesis

United States, Australia, Belgium, United Kingdom, Canada, Sweden
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Repros Therapeutics Inc.

Terminated

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

Endometriosis

United States
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden

3

Subscribe